Net sales were 144,980 million yen (YoY -0.2%), operating loss was 3,679 million yen, and quarterly net loss was 5,773 million yen. Full-year forecasts were revised; impacts related to USM continue. Segment-wise, medical device CDMO and similar businesses were firm, while Devices and Industrial Materials were affected. Dividend policy is maintained. An investor meeting for institutional investors is scheduled for November 11, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7915","jir_company_name":"Nissha Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/7915-20261111-01.pdf","jir_short_summary":"Net sales were 144,980 million yen (YoY -0.2%), operating loss was 3,679 million yen, and quarterly net loss was 5,773 million yen. Full-year forecasts were revised; impacts related to USM continue. Segment-wise, medical device CDMO and similar businesses were firm, while Devices and Industrial Materials were affected. Dividend policy is maintained. An investor meeting for institutional investors is scheduled for November 11, 2026.","jir_summary":"### Overview of Performance\nFor the third quarter of the fiscal year ending December 2026, Nissha Co., Ltd. reported net sales near flat year-on-year. Some segments performed steadily, but the overall result was an operating loss due to weakness in the Devices segment and external factors. In particular, goodwill impairment related to USM and increased production costs for exterior parts weighed on results, turning net income negative. The full-year forecast has been revised, and an investor meeting for institutional investors is scheduled for November 11, 2026.\n\n### Outlook and Impact on Shareholders\nWhile revisions to the full-year forecast are in place, the strength in the medical device CDMO business is expected to provide support. However, demand weakness in Devices and rising costs in Industrial Materials may continue. The current dividend policy remains unchanged, with the recent dividend maintained at 50 yen per year (25 yen x 2). Preventing recurring goodwill impairments and improving productivity are identified as key issues.","jir_financial_highlights":"Net Sales: 144,980 million yen (YoY -0.2%)\nOperating Loss: -3,679 million yen (Operating income in the same period last year was positive (note: the text indicates an operating loss of -3,679 million yen))\nQuarterly Profit (Net Income Attributable to Owners of Parent): -5,773 million yen (The comparable period last year reported a quarterly profit (the text shows 827 million yen quarterly profit))\nFull-Year Net Sales Forecast: 195,000 million yen (0.1% increase)\nDividend: 25.00 yen at end of Q1, 25.00 yen at end of Q2, total 50.00 yen (Same as prior year\u2019s 50.00 yen)","jir_category":"","jir_hashtags":"#Nissha, #Earnings, #FullYearForecastRevision, #InvestorMeeting","jir_key_figures":"Net Sales: 144,980 million yen (YoY -0.2%)\nOperating Loss: -3,679 million yen\nQuarterly Profit: 827 million yen (Quarterly profit attributable to owners of the parent)\nFull-Year Net Sales Forecast: 195,000 million yen (0.1% increase)\nDividend: 25 yen at end of Q1, 25 yen at end of Q2, total 50 yen for the year","jir_meta_title":"Nissha Co., Ltd. Q3 FY2026 Financial Summary | Flat Sales but Net Loss, Full-Year Forecast Revised","jir_meta_description":"Summary of Nissha Co., Ltd.'s Q3 FY2026 financial summary. Net sales were largely flat, with operating and net losses recorded. Full-year forecasts have been revised. Segment trends, key issues going forward, and dividend policy are outlined.","jir_og_title":"Nissha Co., Ltd. Q3 Results and Analysis Following Full-Year Forecast Revision","jir_og_description":"Nissha Co., Ltd. posted an operating loss and net loss in Q3 FY2026 and revised its full-year forecast. Medical device CDMO remains firm, but Devices and Industrial Materials are impacted by rising costs. An investor meeting has been announced.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17150,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149314","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n